Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. reports news on its late-stage clinical biopharmaceutical work in oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company’s principal program centers on obicetrapib, an oral, low-dose CETP inhibitor, evaluated alone and as a fixed-dose combination with ezetimibe as an adjunct to statin therapy.
Recurring updates include Phase 3 clinical data from programs such as BROADWAY, TANDEM, BROOKLYN and PREVAIL, safety and tolerability analyses, regulatory-review activity, financial results, corporate presentations and scientific-conference disclosures. NewAmsterdam also reports Nasdaq inducement grants and other equity-compensation actions tied to its public-company governance.
NewAmsterdam Pharma (Nasdaq:NAMS) will participate in two June 2026 investor conferences focused on healthcare.
Management will join fireside chats at the Jefferies Global Healthcare Conference in New York on June 3 and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 9, with live and archived webcasts via its investor relations site.
NewAmsterdam Pharma (Nasdaq:NAMS) announced participation in two May 2026 investor conferences focused on healthcare and biopharma.
Management will appear at the BofA Securities 2026 Health Care Conference on May 12 in Las Vegas and the RBCCM Global Healthcare Conference on May 20 in New York, with live and archived webcasts.
NewAmsterdam Pharma (Nasdaq: NAMS) reported Q1 2026 results and a corporate update on May 7, 2026. Key points: $707.3M in cash and marketable securities at March 31, 2026; ongoing Phase 3 programs PREVAIL, REMBRANDT, RUBENS; PREVAIL interim planned 4Q26 with result expected 1Q27; RUBENS topline due by year-end 2026; BROADWAY/BROOKLYN pooled analyses published showing safety and kidney-function signals. Management will host a PREVAIL update call today at 8:00 AM ET.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants for five non-executive new hires on May 1, 2026. The Compensation Committee approved 50,400 share options (exercise price $28.43) and 15,400 restricted stock units.
Options vest over four years (25% at one year then 36 monthly installments). RSUs vest over three years (one-third each year). Grants issued under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS) said CFO Ian Somaiya and EVP Matthew Philippe will present in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:45 a.m. ET. A live webcast and archived replay will be available via the company investor relations site.
NewAmsterdam Pharma (Nasdaq: NAMS) approved inducement equity awards for two non-executive hires on April 1, 2026 under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants total 15,000 stock options (exercise price $32.81) and 3,200 restricted stock units, with multi-year vesting schedules tied to continued service.
NewAmsterdam Pharma (Nasdaq: NAMS) will present three digital posters at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28-30, 2026.
The presentations cover obicetrapib kidney outcomes from BROADWAY, a pooled Phase III safety analysis, and LDL particle–CVD risk relationships, with presenters from company leadership and collaborators.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants to two non-executive new hires under its 2024 Inducement Plan on March 2, 2026. The Compensation Committee approved options for 10,000 ordinary shares at an exercise price of $32.83 and 2,200 restricted stock units.
Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years in equal one-third annual installments. Awards are subject to plan and award agreement terms and Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma (Nasdaq: NAMS) announced management will attend investor conferences in early March 2026, including TD Cowen (Boston, Mar 3), Leerink Partners (Miami, Mar 9) and Jefferies Biotech on the Beach (Miami Beach, Mar 10).
Presentations and a fireside chat will be webcast live via the company's investor relations site, with archived replays available after each event.
NewAmsterdam Pharma (Nasdaq: NAMS) reported full-year 2025 results and provided a corporate update highlighting regulatory, clinical and financial milestones. Key items: MAAs accepted in EMA, UK and Switzerland with decisions expected in 2H26; $728.9M cash at 12/31/2025; ongoing Phase 3 PREVAIL, REMBRANDT and RUBENS trials; RUBENS topline expected by year-end 2026; PREVAIL blinded event rate in line with BROADWAY; plan to start an Alzheimer’s trial in 2026.
Revenue fell to $22.5M (2025) from $45.6M (2024); net loss improved to $203.8M from $241.6M; SG&A rose to $106.4M.